title: Delivering affordable cancer care in high-income countries.
abstract: The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.
authors.affiliation: Kings Health Partners, King's College, Integrated Cancer Centre, Guy's Hospital Campus, London, UK. richard.sullivan@kcl.ac.uk
authors.forename: Richard
authors.initials: R
authors.lastname: Sullivan
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Peppercorn
authors.forename: Karol
authors.initials: K
authors.lastname: Sikora
authors.forename: John
authors.initials: J
authors.lastname: Zalcberg
authors.forename: Neal J
authors.initials: NJ
authors.lastname: Meropol
authors.forename: Eitan
authors.initials: E
authors.lastname: Amir
authors.forename: David
authors.initials: D
authors.lastname: Khayat
authors.forename: Peter
authors.initials: P
authors.lastname: Boyle
authors.forename: Philippe
authors.initials: P
authors.lastname: Autier
authors.forename: Ian F
authors.initials: IF
authors.lastname: Tannock
authors.forename: Tito
authors.initials: T
authors.lastname: Fojo
authors.forename: Jim
authors.initials: J
authors.lastname: Siderov
authors.forename: Steve
authors.initials: S
authors.lastname: Williamson
authors.forename: Silvia
authors.initials: S
authors.lastname: Camporesi
authors.forename: J Gordon
authors.initials: JG
authors.lastname: McVie
authors.forename: Arnie D
authors.initials: AD
authors.lastname: Purushotham
authors.forename: Peter
authors.initials: P
authors.lastname: Naredi
authors.forename: Alexander
authors.initials: A
authors.lastname: Eggermont
authors.forename: Murray F
authors.initials: MF
authors.lastname: Brennan
authors.forename: Michael L
authors.initials: ML
authors.lastname: Steinberg
authors.forename: Mark
authors.initials: M
authors.lastname: De Ridder
authors.forename: Susan A
authors.initials: SA
authors.lastname: McCloskey
authors.forename: Dirk
authors.initials: D
authors.lastname: Verellen
authors.forename: Terence
authors.initials: T
authors.lastname: Roberts
authors.forename: Guy
authors.initials: G
authors.lastname: Storme
authors.forename: Rodney J
authors.initials: RJ
authors.lastname: Hicks
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Ell
authors.forename: Bradford R
authors.initials: BR
authors.lastname: Hirsch
authors.forename: David P
authors.initials: DP
authors.lastname: Carbone
authors.forename: Kevin A
authors.initials: KA
authors.lastname: Schulman
authors.forename: Paul
authors.initials: P
authors.lastname: Catchpole
authors.forename: David
authors.initials: D
authors.lastname: Taylor
authors.forename: Jan
authors.initials: J
authors.lastname: Geissler
authors.forename: Nancy G
authors.initials: NG
authors.lastname: Brinker
authors.forename: David
authors.initials: D
authors.lastname: Meltzer
authors.forename: David
authors.initials: D
authors.lastname: Kerr
authors.forename: Matti
authors.initials: M
authors.lastname: Aapro
mesh_terms: D001315:Australia; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D019033:Delivery of Health Care, Integrated / Q000191:economics* / Q000331:legislation & jurisprudence; D005060:Europe; D017048:Health Care Costs / Q000331:legislation & jurisprudence; D018166:Health Care Reform / Q000191:economics; D005102:Health Expenditures / Q000331:legislation & jurisprudence; D006291:Health Policy / Q000191:economics; D006297:Health Services Accessibility / Q000191:economics* / Q000331:legislation & jurisprudence; D006300:Health Services Misuse / Q000191:economics; D006302:Health Services Research; D054625:Healthcare Disparities / Q000191:economics; D006801:Humans; D007348:Insurance, Health / Q000191:economics; D018803:Models, Economic; D009369:Neoplasms / Q000175:diagnosis / Q000191:economics* / Q000628:therapy*; D012959:Socioeconomic Factors; D014481:United States